Search results (52)
« Back to News & OpinionNews and Opinion from the Pandemic Sciences Institute at the University of Oxford
Ambitious research aiming to develop multivalent vaccines to protect against multiple deadly filoviruses
8 January 2026
Working with international partners, scientists across PSI and OVG will design and develop multivalent vaccine candidates with funding from CEPI and Horizon Europe.
Driving the development of new tools to combat Nipah virus outbreaks
18 December 2025
- Ethics, social science & humanities
- Nipah virus
- Pathogen biology & new threats
- Research news
- Vaccines, treatments, diagnostics & trials
PSI’s Nipah Virus Research Day, held on Wednesday, 19 November 2025, showcased promising developments, spanning new insights into Nipah virus biology, clinical trials of vaccines, the development of policy responses, and progress in developing diagnostics and treatments, all of which are helping improve responses to outbreaks of this deadly virus.
International collaboration launches largest-ever therapeutics trial for patients hospitalised with dengue
10 December 2025
A landmark international research collaboration has launched the largest clinical trial ever conducted to test therapeutics for moderate-severe dengue, a mosquito-borne viral disease that continues to spread rapidly driven by climate change and globalisation.
World's first Phase II Nipah virus vaccine trial launch
9 December 2025
The trial will assess the safety and immune response of the ChAdOx1 NipahB vaccine, developed by PSI scientists, in a region where the virus causes recurrent outbreaks.
First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial
4 December 2025
The vaccine developed by PSI researchers aims to advance the fight against Lassa fever virus, a WHO priority pathogen posing a significant public health risk.
PSI-Dr Jenner’s House collaborative school’s programme wins educational award
27 November 2025
The Frances Garnham Award for Education celebrates innovative approaches to educational or community engagement.
New research reveals optimal time intervals for COVID-19 vaccine boosters
1 September 2025
Two new papers from University of Oxford scientists have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
PSI-industry oral vaccine project aims to transform immunisation strategies
18 August 2025
The project led by Professor Dame Sarah Gilbert is one of the winners of the first VaxHub Sustainable Platform Funding Call.
Bubonic plague treatment proven highly effective and safe in global first
6 August 2025
Researchers from the UK and Madagascar, in collaboration with Madagascar’s health services and national plague programme, have conducted the world’s first rigorous clinical trial of treatments for bubonic plague.
HRH The Duke of Gloucester visits University of Oxford’s cutting-edge vaccine facilities
25 July 2025
The visit to the Clinical BioManufacturing Facility and the laboratories of the Oxford Vaccine Group and Pandemic Sciences Institute showcased Oxford’s global leadership in medical science and innovation.
Oxford vaccine against deadly Nipah virus granted European Medicines Agency PRIME designation
9 June 2025
The designation recognises the vaccine’s potential to address the unmet medical need arising from the devastating Nipah virus disease, which can be fatal in up to 85% of cases.
New research published on maximising mpox vaccine availability
5 June 2025
Scientists have studied the immune response of a dose-sparing regimen to expand vaccine supply and protect more people from mpox.
Up to £16.5 million awarded to global consortium to overcome obstacles in infectious disease research
8 April 2025
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has been awarded up to £16.5 million to build on its globally-recognised efforts to prevent illness and deaths from epidemic-prone infectious diseases.
RECOVERY trial team win NIHR Impact Prize
21 March 2025
Co-led by PSI Director Professor Sir Peter Horby, the RECOVERY trial was defined "one of the most well-known studies supported by the NIHR with clear national and global impact”.
New paper outlines ethical issues in clinical metagenomics
7 March 2025
This week, University of Oxford researchers published the first paper mapping clinical ethics questions raised by new metagenomic techniques for diagnosing disease in clinical practice.
Advances in AI can help prepare the world for the next pandemic
19 February 2025
- Epidemiology & data
- Ethics, social science & humanities
- Pathogen biology & new threats
- Research news
- Vaccines, treatments, diagnostics & trials
In the first study of this kind, PSI and Oxford researchers partner with global colleagues to outline how Artificial Intelligence can transform infectious disease research and save more lives.
New partnership to advance public health and life science research collaboration in West Africa
13 February 2025
PSI and Institut Pasteur de Dakar (IPD) will cooperate on developing vaccines and rapid diagnostics – as well as strengthening workforce in the vaccinology, clinical trials and biomanufacturing sectors.
Study provides new insights into mpox clinical outcomes and transmission
16 January 2025
Results of MOSAIC, a European observational study led by researchers at PSI and ISARIC, provides evidence on how the clade IIb mpox virus affects patients and the risks of onward transmission.
Pig research paves way for human respiratory vaccine development
9 January 2025
A study in pigs, which shows that inhaled vaccines could potentially reduce viral transmission and improve efficiency, is an important step toward advancing vaccines for human use.
University of Oxford unveils new vaccine development partnership
15 November 2024
Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian biotech innovator Univercells.